Clinical Characterization and Biorepository Core
Clinical Characterization and Biorepository Core
批准号:
8444001
负责人:
ELIZA F CHAKRAVARTY
金额:
$28.86万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
未结题
起止时间:
2007-09-01 至
关键词:
AddressAlaskaAutoimmune DiseasesCaliforniaChicagoClinicalClinical DataClinical ResearchClinical TrialsClinical assessmentsCodeCollectionConsentDataDiseaseEnrollmentEnsureFamily-Based RegistryFundingFutureGleanGoalsGood Clinical PracticeHealthHealth Insurance Portability and Accountability ActHumanHuman ResourcesHuman Subject ResearchIndividualInformation SystemsInformed ConsentInstitutesLupusMeasurementMeasuresOklahomaParticipantPatientsProceduresProcessProtocols documentationReportingResearchResearch PersonnelResearch Project GrantsResearch TrainingResourcesRheumatismSamplingServicesSocial WelfareSouth CarolinaTherapeuticTrainingVenous blood samplingbasebiobankcareer developmentcohorthuman subjecthuman subject protectioninstrumentmeetingsmemberpatient oriented researchprogramsrepository
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The Clinical Characterization and Biorepository Core (CCBC) provides ORDRCC investigators with access to unique patient collections and new recruitment opportunities to aid their rheumatic disease research programs and to help facilitate their career development. This Core provides a centralized process for patient-oriented research training, patient/control identification and recruitment, and sample processing, as well as access to large collections of patient and control samples with associated clinical, demographic, therapeutic and disease activity measures. Based upon some recent changes in funding, the Clinical Characterization and Biorepository Core will encompass the previous ORDRCC Sample Procurement and Management Core (SPMC), along with samples and data from the historical Lupus Family Registry and Repository, to facilitate the clinical investigation of ORDRCC investigators and junior investigators. The OMRF SPMC was established with the funding of the ORDRCC, and has supported projects from 37 Junior ORDRCC Investigators (both from inside and outside Oklahoma, spanning from South Carolina to Alaska and from Chicago to California) and 19 ORDRCC Center Investigators. The goals of the Clinical Characterization and Biorepository Core are to:
1) Facilitate human subject recruitment, re-contact, consent and compliance. The CCBC ensures that human subject recruitment, clinical assessments and sample donation procedures meet rigorous standards of good clinical practice. By performing services in informed consent, regulatory reporting, oversight of the welfare of clinical study participants, and provision of expert clinical assessments using validated disease activity instruments, the CCBC supports and expands the research opportunities of all ORDRCC investigators.
2) Process and code samples provided to ORDRCC investigators. The CCBC ensures timely, protocol-driven processing, coding, storage and tracking of human biologic samples.
3) Provide samples and associated clinical data to ORDRCC research projects. Extensive clinical, demographic, disease activity and disease damage data exists on patients enrolled with systemic rheumatic diseases. The CCBC will make ORDRCC investigators aware of various patient and control clinical information and associated samples, which will be useful for their various projects.
4) Train ORDRCC junior investigators in human subject research. The ORDRCC helps ensure appropriate HIPAA and human subjects training of all ORDRCC personnel and training of personnel in use of the central OMRF Autoimmune Disease Institute data system.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Clinical Characterization and Biorepository Core
-
批准号:10016170
-
项目类别:
-
资助金额:$30.67万
-
财政年份:2018
-
负责人:ELIZA F CHAKRAVARTY
-
依托单位:
Clinical Characterization and Biorepository Core
-
批准号:10251964
-
项目类别:
-
资助金额:$30.67万
-
财政年份:2018
-
负责人:ELIZA F CHAKRAVARTY
-
依托单位:
Clinical Characterization and Biorepository Core
-
批准号:10478210
-
项目类别:
-
资助金额:$30.67万
-
财政年份:2018
-
负责人:ELIZA F CHAKRAVARTY
-
依托单位:
Antibody Mediated Spontaneous Abortion in Lupus Pregnancies
-
批准号:8639720
-
项目类别:
-
资助金额:$10.18万
-
财政年份:2014
-
负责人:ELIZA F CHAKRAVARTY
-
依托单位:
Clinical Characterization and Biorepository Core
-
批准号:8926216
-
项目类别:
-
资助金额:$28.86万
-
财政年份:2007
-
负责人:ELIZA F CHAKRAVARTY
-
依托单位:
Clinical Characterization and Biorepository Core
-
批准号:8734209
-
项目类别:
-
资助金额:$28.86万
-
财政年份:2007
-
负责人:ELIZA F CHAKRAVARTY
-
依托单位:
Clinical Characterization and Biorepository Core
-
批准号:8535610
-
项目类别:
-
资助金额:$27.42万
-
财政年份:2007
-
负责人:ELIZA F CHAKRAVARTY
-
依托单位:
TREATMENT OF ACTIVE SLE AND THE PREVENTION OF SUBSEQUENT LUPUS FLARES
-
批准号:7605246
-
项目类别:
-
资助金额:$0.06万
-
财政年份:2007
-
负责人:ELIZA F CHAKRAVARTY
-
依托单位:
CLINICAL TRIAL: RITUXIMAB IN SUBJECTS WITH ISN/RPS CLASS III OR IV LUPUS NEPHRIT
-
批准号:7717897
-
项目类别:
-
资助金额:$0.05万
-
财政年份:2007
-
负责人:ELIZA F CHAKRAVARTY
-
依托单位:
EFFICACY OF ABATACEPT IN PATIENTS WITH DIFFUSE SYSTEMIC SCLEROSIS
-
批准号:7717910
-
项目类别:
-
资助金额:$0.26万
-
财政年份:2007
-
负责人:ELIZA F CHAKRAVARTY
-
依托单位:
CLINICAL TRIAL: RITUXIMAB IN SUBJECTS WITH MODERATE TO SEVERE SYSTEMIC LUPUS ERY
-
批准号:7717881
-
项目类别:
-
资助金额:$0.09万
-
财政年份:2007
-
负责人:ELIZA F CHAKRAVARTY
-
依托单位:
RITUXIMAB IN SUBJECTS WITH ISN/RPS CLASS III OR IV LUPUS NEPHRITIS
-
批准号:7605248
-
项目类别:
-
资助金额:$0.06万
-
财政年份:2007
-
负责人:ELIZA F CHAKRAVARTY
-
依托单位:
RITUXIMAB IN SUBJECTS WITH MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS
-
批准号:7605227
-
项目类别:
-
资助金额:$0.64万
-
财政年份:2007
-
负责人:ELIZA F CHAKRAVARTY
-
依托单位:
RITUXIMAB IN SUBJECTS WITH MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS
-
批准号:7375304
-
项目类别:
-
资助金额:$0.18万
-
财政年份:2005
-
负责人:ELIZA F CHAKRAVARTY
-
依托单位:
海外基金